Visiox Pharmaceuticals, a Columbus, OH-based biopharmaceutical company, announced that it has entered into a definitive merger agreement with Ocuvex Therapeutics, Inc. an ophthalmic pharmaceutical company.
The strategic combination is set to position the newly combined entity as an emerging player in the eye care sector with a portfolio of ophthalmic medicines.
Ocuvex Therapeutics is a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders. It boasts a pipeline of near-term ophthalmic medicines.
Led by CEO Ryan S. Bleeks, Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Its products, including OMLONTI® (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%, will grow Ocuvex’s market presence and accelerate the commercialization of these therapeutics.
Going forward, the company will operate under the Ocuvex name, building on Visiox’s commitment to improve the ophthalmic market through collaborations with eye care professionals.
FinSMEs
20/08/2024